Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HTGM

HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis

HTG Molecular Diagnostics logo

About HTG Molecular Diagnostics Stock (NASDAQ:HTGM)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$5.01
$6.80
52-Week Range
N/A
Volume
773,040 shs
Average Volume
294,806 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive HTGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

HTGM Stock News Headlines

HTGMQ HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics Inc HTGMQ
Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
HTG Molecular Diagnostics Inc (HTGMQ)
See More Headlines

HTGM Stock Analysis - Frequently Asked Questions

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its quarterly earnings data on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.60). The medical research company earned $2.52 million during the quarter, compared to analyst estimates of $2.90 million. HTG Molecular Diagnostics had a negative net margin of 324.25% and a positive trailing twelve-month return on equity of 45.52%.

HTG Molecular Diagnostics (HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that HTG Molecular Diagnostics investors own include Sangamo Therapeutics (SGMO), Idera Pharmaceuticals (IDRA), NightHawk Biosciences (NHWK), Abeona Therapeutics (ABEO), Exelixis (EXEL), Bionano Genomics (BNGO) and Adamis Pharmaceuticals (ADMP).

Company Calendar

Last Earnings
11/10/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:HTGM
CIK
1169987
Employees
84
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.59 million
Net Margins
-324.25%
Pretax Margin
-324.05%
Return on Equity
45.52%
Return on Assets
8.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.40
Quick Ratio
1.30

Sales & Book Value

Annual Sales
$6.37 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.44 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,210,000
Free Float
2,156,000
Market Cap
N/A
Optionable
Optionable
Beta
0.99

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:HTGM) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners